← Leaderboards
Bradley E Aouizerat
University Of California, San Francisco
$24,642,745
Attributed
$59,503,291
Total exposure
11
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.1M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$81,618,497 · 12
By mechanism
U01$55,499,356 · 2
R01$19,896,066 · 6
R61$2,425,077 · 1
RM1$1,969,877 · 1
R33$1,377,622 · 1
R21$450,499 · 1
Top collaborators
- Phyllis C Tien24 shared
- Jennifer Cohen Price12 shared
- Ke Xu12 shared
- Christine A. Miaskowski10 shared
- Ruth Martha Greenblatt7 shared
- Eric O Johnson6 shared
- Chi T. Viet2 shared
- Peter W Hunt1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Emmanuelle Passegue$22,475,888
- Aimee Kao$26,280,041
- Trey Ideker$62,370,509
- Tracey J. Woodruff$21,216,565
- Nevan J Krogan$73,195,859
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCohortHiv InfectionsLinkSamplingCohort StudiesAgingBiologicalEpigenomicsEpigenetic ProcessPathway InteractionsGeneticAreaParticipantWomen&AposMorbidity - Disease RateComorbidityBaseMalignant NeoplasmsAnti-Retroviral AgentsWomanEnrollmentGenomicsResearch Personnel
Grant awards (56)
SF Bay Area MACS/WIHS Combined Cohort Study$4,444,509
U01 · FY2025 · HL
Stimulant and Polysubstance use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE)$1,969,877
RM1 · FY2025 · DA
Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis$999,317
R01 · FY2025 · DA
PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool$679,280
R01 · FY2025 · CA
SF Bay Area MACS/WIHS Combined Cohort Study$4,678,523
U01 · FY2024 · HL
Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis$1,032,192
R01 · FY2024 · DA
PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool$710,656
R01 · FY2024 · CA
SF Bay Area MACS/WIHS Combined Cohort Study$4,514,463
U01 · FY2023 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$4,486,070
U01 · FY2022 · HL
Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir$601,331
R33 · FY2022 · DA
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$561,829
R01 · FY2022 · DA
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$379,063
R01 · FY2022 · DA
Proteomic Profiling of Cardiac Dysfunction in the MACS-WIHS Combined Cohort Study$159,619
U01 · FY2022 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$4,701,219
U01 · FY2021 · HL
Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir$776,291
R33 · FY2021 · DA
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$570,656
R01 · FY2021 · DA
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$363,122
R01 · FY2021 · DA
Assessing Function and Performance of Population Sexual Orientation and Gender Identity (SOGI) Research Measures in a Racially Diverse HIV-Specific National Cohort$99,777
U01 · FY2021 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$44,725
U01 · FY2021 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$4,303,903
U01 · FY2020 · HL
Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir$853,917
R61 · FY2020 · DA
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$595,425
R01 · FY2020 · DA
SF Bay Area MACS/WIHS Combined Cohort Study$519,977
U01 · FY2020 · HL
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$517,732
R01 · FY2020 · DA
SF Bay Area MACS/WIHS Combined Cohort Study$462,848
U01 · FY2020 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$105,189
U01 · FY2020 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$64,304
U01 · FY2020 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$3,300,000
U01 · FY2019 · HL
SF Bay Area MACS/WIHS Combined Cohort Study$1,418,791
U01 · FY2019 · HL
Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir$782,553
R61 · FY2019 · DA
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$599,984
R01 · FY2019 · DA
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$592,854
R01 · FY2019 · DA
HIV Latent Reservoir Equipment$98,000
R61 · FY2019 · DA
SF Bay Area MACS/WIHS Combined Cohort Study$80,233
U01 · FY2019 · HL
The Connie Wofsy Women's HIV Study$4,181,287
U01 · FY2018 · AI
Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir$690,607
R61 · FY2018 · DA
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$606,847
R01 · FY2018 · DA
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$562,739
R01 · FY2018 · DA
The Connie Wofsy Women's HIV Study$4,122,513
U01 · FY2017 · AI
The Connie Wofsy Women's HIV Study$4,115,106
U01 · FY2016 · AI
Epigenetic Markers of Age and Diurnal Levels of Fatigue during Chemotherapy$198,125
R21 · FY2016 · NR · contact PI
The Connie Wofsy Women's HIV Study$3,180,566
U01 · FY2015 · AI
Epigenetic Markers of Age and Diurnal Levels of Fatigue during Chemotherapy$252,374
R21 · FY2015 · NR · contact PI
The Connie Wofsy Women's HIV Study$3,122,179
U01 · FY2014 · AI
Characterization of and Treatment for Chemotherapy Neuropathy$1,260,254
R01 · FY2014 · CA
Symptoms Clusters in Oncology Patients Receiving Chemotherapy$895,046
R01 · FY2014 · CA
The Connie Wofsy Women's HIV Study$42,196
U01 · FY2014 · AI
The Connie Wofsy Women's HIV Study$3,351,359
U01 · FY2013 · AI
Characterization of and Treatment for Chemotherapy Neuropathy$1,268,014
R01 · FY2013 · CA
Symptoms Clusters in Oncology Patients Receiving Chemotherapy$1,031,035
R01 · FY2013 · CA
Characterization of and Treatment for Chemotherapy Neuropathy$1,349,495
R01 · FY2012 · CA
Symptoms Clusters in Oncology Patients Receiving Chemotherapy$1,280,902
R01 · FY2012 · CA
Characterization of and Treatment for Chemotherapy Neuropathy$1,387,597
R01 · FY2011 · CA
Symptoms Clusters in Oncology Patients Receiving Chemotherapy$356,932
R01 · FY2011 · CA
Symptoms Clusters in Oncology Patients Receiving Chemotherapy$1,222,381
R01 · FY2010 · CA
Symptoms Clusters in Oncology Patients Receiving Chemotherapy$1,072,714
R01 · FY2009 · CA